Status:
COMPLETED
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Stroke
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen A...
Eligibility Criteria
Inclusion
- Patient registered in the Chinese Stroke Centre Alliance (CSCA) platform from Aug 2015 to Jul 2019
- ≥18 years old
- Diagnosed as Acute Ischemic Stroke (AIS) at admission
- Arrived or admitted into hospital within 4.5 hours of symptom onset
- For patients in the iv rt-PA groups only: received IV rt-PA within 4.5 hours of symptom onset
Exclusion
- Documented Intravenous Thrombolysis (IVT) absolute contraindication
- Key data missing (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, IVT treated or not, time of IV alteplase treatment)
- Received thrombolysis agents other than IV rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)
- Received endovascular treatment
- Received IV rt-PA after 4.5 hours of symptom onset
Key Trial Info
Start Date :
November 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 28 2023
Estimated Enrollment :
113035 Patients enrolled
Trial Details
Trial ID
NCT05395351
Start Date
November 30 2022
End Date
March 28 2023
Last Update
December 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim (China) Investment Co., ltd.
Shanghai, China, 200040